Business
R&D Partnership with Green Cross LabCell
R&D Partnership with Green Cross LabCell.
About this update from Oxford Biomedica Plc
[{"type":"text","content":"\n \nRNS Number : 0223A Oxford Biomedica PLC 02 June 2016 \n\n \n \n \n \n \n \nOxford BioMedica and Green Cross LabCell form a Partnership to Develop Gene-modified NK Cell Therapeutics in cancer \n \nUnique combination of Oxford BioMedica's LentiVector® delivery platform and Green Cross LabCell's NK cell platform to generate a pipeline of differentiated products in cancer\n \nOxford, UK & Seoul, Korea - 2 June 2016: Oxford BioMedica plc (\"Oxford BioMedica\" or \"the Group\") (LSE: OXB), a leading gene and cell therapy group, today announces that it has entered into a Research & Development Collaboration with Green Cross LabCell (\"GCLC\"), a subsidiary of Green Cross Holdings, a leading South Korean biopharmaceutical company that delivers life-saving and life-sustaining protein therapeutics and vaccines. The collaboration will focus on identifying and developing gene modified natural killer (NK) cell-based therapeutics for treatment of life-threatening diseases such as cancer. \nThis collaboration brings together two clinically validated platform technologies with the aim of generating a pipeline of novel and differentiated cell-based products in areas of serious unmet medical need. Oxford BioMedica is contributing its clinically tested LentiVector® gene delivery platform for the efficient modification of immune cells, as well as its expertise in GMP bioprocessing, clinical development and regulatory affairs in ex vivo cell & gene therapy. GCLC is contributing its clinically tested platform for production of highly potent and activated NK cells. \nDuring the initial Research Collaboration, Oxford BioMedica and GCLC (the \"Parties\") will collaborate to identify potential NK cell-based product candidates, modified using lentiviral vectors. The collaboration will focus on allogeneic CAR-NK cell-based products. Under the terms of the agreement, Oxford BioMedica and GCLC will share the costs associated with the Research Collaboration equally. Oxford BioMedica's contribution to the Research Collaboration will be funded from its existing Discovery resources and budget. The Parties will agree which product candidates from the Research Collaboration will be taken forward into the Development Collaboration stage of the programme on a product-by-product basis. \nAfter nearly a de...